Skip to main content
Fig. 2 | Clinical Sarcoma Research

Fig. 2

From: Good and sustained response to pembrolizumab and pazopanib in advanced undifferentiated pleomorphic sarcoma: a case report

Fig. 2

Axial (a) and coronal (b) fused positron emission tomography—computed tomography (PET-CT) images showing 18-fluorodeoxyglucose (18-FDG) avid soft tissue nodule in the left lung upper lobe (green arrows) after completion of gemcitabine-docetaxel chemotherapy. CT scan images (c, d) in lung window showing progression of nodules in left lung upper lobe (red arrows) after 3 months of watchful waiting. 18-FDG PET-CT scan images showing reduction in size with resolution of metabolic activity of lung nodules after 3 months (e, f) (blue arrows) and 9 months (g, h) (white arrows) of treatment with pembrolizumab + pazopanib

Back to article page

Clinical Sarcoma Research

ISSN: 2045-3329